AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10806134
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg)
Trial: 10546920
Drug: Irbesartan (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (150 mg)
Trial: 19088467
Drug: Subcutaneous epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous epoetin
Trial: 19088467
Drug: Intravenous epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous epoetin
Trial: 7639807
Drug: High-dose omega
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose omega 3 fatty acids (130 mg/kg/day)
Trial: 2619780
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (twice-daily dosage)
Trial: 15925816
Drug: Gefitinib (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib (250 mg orally once a day) and Anastrozole (1 mg orally once a day)
Trial: 19944363
Drug: Moderate sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate sodium restriction (120mmol to 2.8g/day) plus oral furosemide (125 to 250mg bid)
Trial: 19944363
Drug: Low-sodium diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-sodium diet (80mmol to 1.8g/day) plus oral furosemide (125 to 250mg bid)
Trial: 11432485
Drug: Meropenem (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (50 mg/kg/dose, maximum 1 g, every 8 hours)
Trial: 11432485
Drug: Piperacillin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin (200 mg/kg/dose, every 6 hours) plus Amikacin (15 mg/kg daily)
Trial: 9712234
Drug: IgG serology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG serology (Orion Diagnostica Pyloriset New EIA‐G)
Trial: 9712234
Drug: Capsule 14C
RxNorm normalized name: urea [14C]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule 14C urea breath test (UBT)
Trial: 9712234
Drug: Non-capsule UBT
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-capsule UBT
Trial: 9712234
Drug: Capsule UBT
RxNorm normalized name: MERETEK UBT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule UBT
Trial: 8308505
Drug: Fluticasone aqueous
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone aqueous nasal spray 200 micrograms once daily
Trial: 2658700
Drug: Inhaled propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled propranolol
Trial: 28364870
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogen (o-CEE, 0.45mg/day)
Trial: 28364870
Drug: Transdermal 17β
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17β estradiol (t-E2, 50μg/day)
Trial: 28364870
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment groups (o-CEE, t-E2)
Trial: 17205825
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg once per day after breakfast for 8 weeks
Trial: 17205825
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Xiaoyao Decoction (XD) and Wendan Decoction (WD) one dose a day before supper for 8 weeks
Trial: 1718366
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg Cu/d
Trial: 31329216
Drug: AZD0530 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD0530 (100 mg or 125 mg daily)
Trial: 15063421
Drug: Sildenafil (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (25 to 100 mg thrice daily)
Trial: 9070958
Drug: Aspirin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (50 mg) plus dipyridamole (150 mg/day)
Trial: 9070958
Drug: Aspirin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (50 mg) plus ticlopidine (200 mg/day)
Trial: 3723262
Drug: WHO recommended
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [WHO Recommended Hand Rub]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WHO recommended glucose ORS (20 g/L of glucose)
Trial: 29856344
Drug: Inactivated varicella
RxNorm normalized name: VARICELLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated varicella zoster vaccine (vaccine consistency lot group)
Trial: 20013055
Drug: Chlorella supplementation
RxNorm normalized name: Chlorella emersonii extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorella supplementation (6 g daily from 12th-18th week of gestation until delivery)
Trial: 10505808
Drug: EDTA solution
DrugBank: Edetate sodium (DB13404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDTA solution (pH 7.4)
Trial: 10505808
Drug: Saturated citric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saturated citric acid solution (pH 1)
Trial: 30235286
Drug: HIV-1 multiantigen
RxNorm normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1 multiantigen DNA vaccine (HIV-MAG, 3000 μg) co-administered with IL-12 plasmid DNA adjuvant (0, 250, 1000, or 1500 μg) via electroporation.
Trial: 22632452
Drug: Canagliflozin 50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin 50, 100, 200, 300 mg daily or 300 mg twice daily
Trial: 22632452
Drug: Placebo/Sitagliptin 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo/Sitagliptin 100 mg daily
Trial: 20562541
Drug: Vibration therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibration therapy
Trial: 18097228
Drug: Current antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current antihypertensive therapy
Trial: 17259790
Drug: One daily
RxNorm normalized name: One Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One daily GH injection
Trial: 17259790
Drug: Two daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two daily GH injections
Trial: 12716484
Drug: IFN-beta1b treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-beta1b treatment (16 patients)
Trial: 9165428
Drug: Endovenous phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endovenous phenytoin (PHT) - two infusions (mean dosage of 18 mg/kg; mean time of 1 hr)
Trial: 9165428
Drug: Endovenous phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endovenous phenytoin (PHT) - one infusion
Trial: 4091994
Drug: Phenytoin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin 0.5 g
Trial: 20171422
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (dispersible tablets) of MMF 1.0 g
Trial: 20171422
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (capsules) of MMF 1.0 g
Trial: 12173198
Drug: 0.15% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15% ropivacaine plus sufentanil 0.5 microgram ml-1
Trial: 339846
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied caffeine 30%-hydrocortisone 0.5% in hydrophilic ointment
Trial: 339846
Drug: Hydrocortisone 0.5%
RxNorm normalized name: HYDROCORTISONE 0.5% OINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 0.5% in hydrophilic ointment
Trial: 9794948
Drug: Late surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late surfactant treatment
Trial: 6142208
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no surfactant treatment)
Trial: 28697127
Drug: Celecoxib 400
RxNorm normalized name: celecoxib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 400 mg orally 1 hour before ERCP
Trial: 28697127
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion only (control group)
Trial: 22175055
Drug: PSMC +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSMC + 300 mL of magnesium citrate (M)
Trial: 18710606
Drug: EGCG (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGCG (400 mg capsules, twice daily for 8 weeks)
Trial: 18710606
Drug: Placebo (lactose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lactose, twice daily for 8 weeks)
Trial: 16359745
Drug: 0.4 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 g/kg alcohol (2 drink equivalent)
Trial: 6395526
Drug: Bencyclan (2x
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bencyclan (2x 200 mg daily for 8 weeks)
Trial: 20568656
Drug: St. John's
RxNorm normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St. John's wort extract WS 5570 (600-1800 mg/day)
Trial: 15580433
Drug: Maxout implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxout implant
Trial: 15580433
Drug: Maxout implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxout implant (intraoral placement)
Trial: 15580433
Drug: Maxout implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxout implant (transnasal replacement)
Trial: 10476242
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of interferon beta-1a administered once weekly
Trial: 894798
Drug: Massive penicillin
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Massive penicillin dosage (60 million units)
Trial: 894798
Drug: Ticarcillin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticarcillin (200 mg. per kg.)
Trial: 31150976
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group with PFOA concentration > median (4.9 ng/mL)
Trial: 17267928
Drug: Internet-based cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive-behavioural therapy with telephone support
Trial: 2109473
Drug: Flumazenil 1
RxNorm normalized name: flumazenil 100 % MISCELL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil 1 mg
Trial: 9135873
Drug: HIV protease
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV protease inhibitor saquinavir (SQV) in combination with zidovudine (ZDV)
Trial: 7520906
Drug: Risperidone (6,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (6, 10, 16 mg/day)
Trial: 11530275
Drug: Haloperidol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (10 mg/day)
Trial: 11453313
Drug: Inhaled formoterol
RxNorm normalized name: formoterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled formoterol
Trial: 1092411
Drug: Subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin calcium 5000 IU every eight hours for six days
Trial: 31387868
Drug: Pivotal Response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pivotal Response Treatment Package (PRT‐P)
Trial: 25031380
Drug: Standardized physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized physical therapy
Trial: 23332882
Drug: Solifenacin 5mg
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solifenacin 5mg once daily
Trial: 22150035
Drug: Isoniazid-only group
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid-only group (isoniazid 300 mg for 9 months)
Trial: 22184370
Drug: AMG 386
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 386 10 mg/kg QW plus paclitaxel
Trial: 22184370
Drug: AMG 386
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 386 3 mg/kg QW plus paclitaxel
Trial: 12458361
Drug: Al-adjuvanted low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Al-adjuvanted low-dose formulations (1.9 micro g HA/strain per dose)
Trial: 12458361
Drug: Al-adjuvanted low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Al-adjuvanted low-dose formulations
Trial: 12458361
Drug: Standard split
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard split virus vaccine (Fluarix)
Trial: 12458361
Drug: Al-adjuvanted whole
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Al-adjuvanted whole virus formulations with reduced antigen content
Trial: 12458361
Drug: Al-adjuvanted whole
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Al-adjuvanted whole virus vaccines with low HA content
Trial: 9593249
Drug: Mechanical plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical plus oral metronidazole (n = 20)
Trial: 9593249
Drug: Polyethylene glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyethylene glycol preparation (n = 21)
Trial: 26445139
Drug: Inhaled placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled placebo
Trial: 2242972
Drug: Defibrotide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide (400 mg b.i.d., intramuscular injection, starting one day before surgery and continuing for seven postoperative days)
Trial: 2242972
Drug: Calcium heparin
RxNorm normalized name: HEPARIN CALCIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium heparin (5000 IU t.i.d., subcutaneous injection, starting two hours before surgery and continuing for seven days)
Trial: 8027144
Drug: Calcium heparin
RxNorm normalized name: HEPARIN CALCIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium heparin
Trial: 22268852
Drug: Aspirin 81
RxNorm normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 81 mg/day plus Clopidogrel 75 mg/day
Trial: 7664901
Drug: Pre-operative radiation
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative radiation therapy alone (R)
Trial: 2701039
Drug: Propranolol 120‐480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 120‐480 mg daily, mean dose 280 mg for 6‐9 weeks
Trial: 2701039
Drug: Pindolol 10‐35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol 10‐35 mg daily, mean dose 22 mg for 6‐9 weeks
Trial: 67468
Drug: Intrathecal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal administration of 200 units of antitetanus serum (A.T.S.) (horse)
Trial: 21503000
Drug: Celecoxib 400
RxNorm normalized name: celecoxib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 400 mg once daily (933 subjects)
Trial: 12815302
Drug: Selective endothelin
RxNorm normalized name: endothelial growth factor A, vascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective endothelin receptor-A antagonist BQ-123 administered by the intracoronary route
Trial: 6756632
Drug: Cefotaxime perioperatively
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime perioperatively plus postoperative doses every six hours for 24 hours
Trial: 6756632
Drug: Cefazolin perioperatively
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin perioperatively plus postoperative doses every six hours for 24 hours
Trial: 31383609
Drug: Silver nanoparticle
RxNorm normalized name: Silver nanoparticle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver nanoparticle gel (SG)
Trial: 28515079
Drug: Acetaminophen (APAP)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (APAP) 1,000 mg/6 h for 24 h before and immediately following RE
Trial: 19149344
Drug: Intranasally administered
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasally administered oxymetazoline
Trial: 19149344
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered pseudoephedrine
Trial: 9596418
Drug: Intravenous boluses
RxNorm normalized name: phenylbutazone
DrugBank: Phenylbutazone (DB00812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous boluses of isosorbide dinitrate
Trial: 9596418
Drug: Sublingual sprays
RxNorm normalized name: Sublingual Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual sprays of isosorbide dinitrate
Trial: 20642206
Drug: mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: mometasone furoate nasal spray (200 microg)
Trial: 18560141
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy (eye open)
Trial: 18560141
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy (eye closed)
Trial: 18560141
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy (patient 2)
Trial: 16369892
Drug: HRT (conjugated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT (conjugated estrogen at a dose of 0.31 mg/day + medroxyprogesterone acetate 2.5 mg/day)
Trial: 2179362
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose quinidine-mexiletine combination therapy
Trial: 6805621
Drug: Slow-release hydralazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release hydralazine 200 mg once daily
Trial: 29379943
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of mixed tocotrienols twice daily for 12 months
Trial: 19167122
Drug: Short-term chemotherapy
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term chemotherapy (cisplatin 70 mg/m² for 1 day and 5FU 700 mg/m² for 5 days) with radiotherapy (RT) of 60Gy/30 fractions/7 weeks.
Trial: 19167122
Drug: Protracted chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protracted chemotherapy (cisplatin 7 mg/m² for 10 days and 5FU 250 mg/m² for 14 days) with radiotherapy (RT) of 60Gy/30 fractions/7 weeks.
Trial: 9625122
Drug: Alendronate 10
RxNorm normalized name: ALENDRONATE 10MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 10 mg/day
Trial: 15688191
Drug: Intranasal salmon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal salmon calcitonin (sCT) 200 IU/day
Trial: 10919021
Drug: Endoscopic injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic injection sclerotherapy with ligation (EISL)
Trial: 19626475
Drug: Gadopentetate dimeglumine
RxNorm normalized name: Gadopentetate Dimeglumine
DrugBank: Gadopentetic acid (DB00789)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gadopentetate dimeglumine (0.2 ml/kg)
Trial: 2120987
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline, 0.2 ml/kg)
Trial: 917259
Drug: Intravenous heroin
RxNorm normalized name: heroin
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heroin administration
Trial: 9314855
Drug: Saline placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo administration
Trial: 19356306
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of docosahexaenoic acid (DHA)
Trial: 12486792
Drug: Fluconazole at
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole at 100-400 mg daily for the first 1-3 months post-liver transplantation
Trial: 12486792
Drug: Inhaled liposomal
RxNorm normalized name: amikacin liposomal Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled liposomal preparations post-organ transplantation or preemptive use of itraconazole
Trial: 12486792
Drug: Molecular diagnostic
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecular diagnostic techniques for identification and preemptive therapy
Trial: 16875470
Drug: Contractubex gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contractubex gel
Trial: 2193980
Drug: Aspirin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (1 g per day)
Trial: 24668638
Drug: Ropivacaine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (20 mg)
Trial: 24668638
Drug: Dicaine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dicaine (20 mg)
Trial: 19436994
Drug: Low-dose ketamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketamine (n=15)
Trial: 19436994
Drug: High-dose ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ketamine (n=16)
Trial: 9683310
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation with antioxidant vitamins (vitamin C, 120 mg; vitamin E, 30 mg; beta-carotene, 6 mg) and minerals (selenium, 100 microg; zinc, 20 mg)